Background: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors show promising results in metastatic breast cancer. However, an increased incidence of adverse events is remarkable. Among others, gastrointestinal (GI) involvement is of momentous impact on patients and their quality of life. Methods: Our search included PubMed, ASCO, ESMO and SABCS databases. Randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors were identified and considered relevant based on providing a sufficient safety profile on the incidence of adverse GI effects. Results: Of the 999 records initially screened for relevance, 33 articles were found relevant and 4 studies were finally eligible for meta-analysis with a total of 2007 patients. The relative risk (RR) for all-grade nausea was 1.48 [95% confidence interval (CI): 1.12-1.93, p = 0.005], vomiting was 1.74 (95% CI: 1.09-2.76, p = 0.02), decreased appetite was 1.42 (95% CI: 1.07-1.88, p = 0.02), and for diarrhea it was 1.44 (95% CI: 1.19-1.74, p = 0.0002). Meanwhile, the RR for high-grade nausea was 1.10 (95% CI: 0.29-4.13, p = 0.89), vomiting was 1.38 (95% CI: 0.25-7.75, p = 0.72), decreased appetite was 4.00 (95% CI: 0.87-18.37, p = 0.07), and highgrade diarrhea was 1.19 (95% CI: 0.44-3.21, p = 0.73). Conclusion: Selective CDK4/6 inhibitors were not associated with higher-grade GI toxicities reflecting a well-tolerated safety profile. Regarding the increase in all-grade GI toxicities, it needs further caution with addition of cytotoxic chemotherapy.
Introduction
Targeting the cyclin D-CDK4/6-Rb pathway was an alluring task. Other targeted therapies used to tackle growth signals are usually compensated for by the redundancy of those pathways, hence developing resistance is very common. 1, 2 In contrast, CDK4/6 inhibitors interrupt the most crucial point in the life of the cell (known as the restriction point) when the cell decides to pass from G1 to S phase and pursue another cycle of cell division. 3 This critical point is controlled by a well-defined, nonredundant, evolutionarily conserved pathway which is known as the cyclin D-CDK4/6-Rb pathway. 4 Cyclin D complexes with CDK4/6 that in turn phosphorylates Rb protein and prevents it from stopping the cell cycle. In 2004, Fry and colleagues 5 showed that the specific CDK4/6 inhibitor, palbociclib, has potent antiproliferative effects against Rb-proficient tumor cell lines and human tumor xenografts. Further reports in knockdown mice models revealed that either downregulation of CDK4 expression in mammary epithelial cells or mutant cyclin D1 caused resistance to tumorigenesis mediated by certain oncogenes. 6, 7 This reflects that the intact cyclin D1-CDK4-Rb pathway is instrumental for initiating breast cancer. In the following years, many clinical trials have been initiated to test efficacy and safety of CDK4/6 inhibitors in breast cancer. In 2014, results of the PALOMA-1 trial indicated double the rate of progression-free survival of metastatic breast cancer patients receiving palbociclib and letrozole versus those receiving letrozole only. 8 This was further confirmed by the phase III PALOMA-2 trial. 9 Both trials led to a United States Food and Drug Administration (US FDA) approval of a palbociclib/letrozole combination for metastatic breast cancer. Another combination of palbociclib/fulvestrant was also approved based on recent results from the PALOMA-3 trial. 10 Nevertheless, the adverse effects associated with this newly introduced class of drugs were remarkable and might be troublesome in the palliative setting especially with long term use. Gastrointestinal (GI) adverse effects such as nausea, vomiting and diarrhea are universal events of most anticancer drugs so, it is essential to analyze the exact burden added from CDK4/6 inhibitors in this regard. 
Material and methods

Literature search strategy
Inclusion and exclusion criteria
We included trials that met the following criteria:
(1) phase II or III randomized clinical trials recruiting patients with breast cancer; (2) patients had to be randomly assigned to a CDK4/6 inhibitor (including palbociclib, ribociclib and abemaciclib) or control (placebo treatment); and (3) rate of GI toxicity was given along with an assessable sample size. The following were the exclusion criteria: (1) phase I trials;
(2) nonrandomized trials;
(3) duplicates of previous publications on the same population; and (4) insufficient reporting of the safety data. A flowchart of all the steps of the systematic review is depicted in Figure 1 .
Data extraction
A standardized protocol for data abstraction was used by two independent reviewers (LK, KS) to extract the following information from each study: surname of first author, year of publication, study phase, treatment arms, number of patients evaluable for analysis, number of patients that developed all-grade and high-grade (grade 3/4) nausea, vomiting, diarrhea and decreased appetite.
Statistical analysis
For each GI adverse event, relative risk (RR) and corresponding 95% confidence interval (CI) were the main effect measure. The number of events of each adverse effect was compared between participants assigned to the CDK4/6 inhibitors arm or control treatment arm in each eligible trial. Outcome heterogeneity among the studies in this analysis was checked by Cochrane's Q test. To avoid the potential heterogeneity resulting from the use of two different CDK 4/6 inhibitors (palbociclib versus ribociclib) in the analysis, a random effect model was used in the subanalyses. Review Manager, version 5.3 (Nordic Cochrane Centre; Copenhagen, Denmark) was used for data analyses.
Results
Characteristics of the studies
A total of 992 records were identified through a PubMed search with 7 records from additional sources. After screening the title/abstract, only 33 articles were found relevant. Further data retrieval from relevant full-text articles yielded a further four studies that were eligible for meta-analysis (three were phase III and one was phase II). Causes of exclusion are outlined in Figure 1 along with the process of systematic review. A total of two studies 9,12 compared a combination of palbociclib with letrozole versus letrozole alone in postmenopausal ER+/HER2-advanced breast cancer, one 10 compared palbociclib with fulvestrant versus fulvestrant alone in pre-and postmenopausal women, the last one 13 compared ribociclib with letrozole versus letrozole alone in postmenopausal women. Overall, two studies used abemaciclib 14 and ribociclib 15 in neoadjuvant settings and they were excluded because they did not report complete safety data and the period of drug intake did not exceed 14 days.
The meta-analysis included a total of 2007 patients; the majority of them had an Eastern Cooperative Oncology Group (ECOG) performance score ⩽1 (see Table 1 ). No exclusion criteria of patients with chronic GI diseases were found. The risk of bias was assessed using Cochrane risk of bias tool and results are shown in Figure 2 .
Incidence of GI adverse effects
In the intervention arm (either palbociclib or ribociclib), the incidence of all-grade GI toxicities ranged for nausea 24.5-51.5%, vomiting 14-29.3%, diarrhea 19.1-35%, and for decreased appetite 12.8-18.6%. On the other hand, the incidence of high-grade (3-4) nausea was 1-2.4%, vomiting 0-3.6%, diarrhea 0-4%, and decreased appetite 0-1.5% (See Table 2 ).
RR of GI toxicities
The RR for all-grade nausea was 1.48 (95% CI: 1.12-1.93, p = 0.005), for all-grade vomiting was 1.74 (95% CI: 1.09-2.76, p = 0.02), for all-grade decreased appetite 1.42 (95% CI: 1.07-1.88, p = 0.02) for all-grade diarrhea 1.44 (95% CI: 1.19-1.74, p = 0.0002). Meanwhile, the RR for highgrade (grade 3/4) nausea was 1.10 (95% CI: 0.29-4.13, p = 0.89), for high-grade vomiting 1.38 (95% CI: 0.25-7.75, p = 0.72) for high-grade diarrhea 1.19 (95% CI: 0.44-3.21, p = 0.73), and for high-grade decreased appetite 4.00 (95% CI: 0.87-18.37, p = 0.07). Although all-grade GI toxicities were associated with significantly higher RR in the CDK4/6 inhibitors arm versus control treatment, the high-grade toxicities were nonsignificantly higher. Figures 3-6 illustrate the forest plots for all-grade and high-grade GI adverse effects for palbociclib and ribociclib versus the control treatment.
Given that the analysis comprises two different drugs in the intervention arm, a subgroup analysis was performed (palbociclib versus ribociclib). The variation in the mean effects in the two subgroups was significant in all-grade vomiting, high-grade vomiting and high-grade decreased appetite otherwise no significant subgroup difference was found in remaining toxicities. Interestingly, the ribociclib subgroup was associated with increased risk of all-grade and high-grade vomiting, but CI, confidence interval with lower risk of high-grade decreased appetite in comparison with the palbociclib subgroup. However, it has to be noted that the total number of studies in these analyses is too small to get a confident conclusion about differences in toxicities between the two agents. Furthermore, it is not clear if any GI toxicities were contributors to dose modifications or discontinuation of treatment. There was no significant increase in treatment-related deaths due to GI toxicities.
Discussion
To the best of our knowledge, this is the first analysis to assess the risk of GI toxicities associated with CDK 4/6 inhibitors. Our analysis suggests that adding a CDK 4/6 inhibitor to hormonal therapy marginally increased the incidence of any-grade decreased appetite, nausea, vomiting and diarrhea with no significant increase in the risk of high-grade GI toxicities compared with control.
Chemotherapeutics usually exert their GI adverse effects through their toxic effect on the rapidly proliferating GI mucosa. In addition, other antineoplastic agents may cause nausea and vomiting by directly acting on the vomiting center in the brain. CDK 4/6 inhibitors act by releasing the inhibition of the Rb protein so that it can exert its role as a G1-S cell cycle check point. As a result, cell cycle arrest in quiescent phases occurs with marked inhibition of cancer cells and also normal cell proliferation. 16 Of the normal tissues, one of the most vulnerable tissues to this antiproliferative action is the GI epithelium. In mouse models, it was evident that the binding of cyclin D3 to CDK4 and 6 is essential for intestinal epithelial cell proliferation. 17 It is noteworthy that the effect of the cyclin D-CDK4/6 pathway in the GI epithelial cells is complex. GI symptoms do not only develop due to the direct toxic effect on mucosa, but also due to functional defects in certain brushborder enzymes, disturbances in cellular response to injury and interplay with other pathways. [17] [18] [19] Of those pathways interacting with CDK4/6, Wnt/β-catenin, mitogen-activated protein kinase and nuclear factor (NF)-kB contribute largely to physiology of Gut. 3, 20 Despite the increase in all-grade GI toxicities, there was no significant increase in the grade 3-4 toxicities; this is quite reassuring with the expanding use of such drugs in patients with metastatic breast cancer. As suggested in preclinical studies, the antiproliferative effect of CDK4/6 inhibitors may differ between malignant and normal cells with more profound and longer inhibition of the malignant clones than with normal cells, which recover rapidly with minimal permanent damage. 21 In the phase I trial of palbociclib, 22 the most common dose-limiting toxicity was neutropenia and surprisingly it was not associated with concomitant diarrhea. Furthermore, the increased side effects associated with addition of palbociclib in the PALOMA3 study did not lead to deterioration in the patient-reported quality of life outcomes published by Harbeck and colleagues. 23 The management of GI symptoms induced by CDK 4/6 inhibitors is not yet well established. It should also be noted that palbociclib has (as with other targeted therapies) serious drug interactions with several medications; of interest here are those drugs commonly used to treat GI symptoms. For example, in an early phase drug-interaction study on healthy participants, administration of multiple doses of the proton pump inhibitor rabeprazole, decreased serum concentration of palbociclib by 41%; such interference is expected to be minimal with the use of histamine 2 blockers and local antacids. 24 Moreover, two of the most common drugs used to treat chemotherapy-induced nausea and vomiting should not be used to treat palbociclibinduced nausea and vomiting: dexamethasone and aprepitant. By either inducing or inhibiting the CYP3A4 enzyme, dexamethasone and aprepitant may decrease or increase palbociclib serum levels respectively. 24 In that aspect, metoclopramide and domperidone appear to be well tolerated with CDK 4/6 inhibitors. These interaction patterns should be taken into account in future studies combining CDK 4/6 inhibitors with cytotoxic chemotherapy.
During the peer review process of this article, the results of the MONARCH 2 study were published. In this phase III study, patients progressing on firstline hormonal therapy were randomized to either fulvestrant alone or fulvestrant and abemaciclib. In concordance with our findings, addition of abemaciclib was associated with significant increase in the risk of all-grade diarrhea, nausea and vomiting. 25 However, our analysis has some potential weaknesses and results should be taken cautiously. First, the GI toxicities might be caused by some of the concomitant medications/diseases that patients with metastatic breast cancer might use/suffer from. Such medications/diseases were not accounted for in our analysis and may confound the results. Second, our study included two different CDK 4/6 inhibitors (palbociclib and ribociclib) and two different hormonal backbones (letrozole and fulvestrant) and such heterogeneity may influence the outcome. Finally, this was not an individual data level analysis 26 , meaning that individual confounders were not taken into account.
In conclusion, our analysis shows that the use of CDK 4/6 inhibitors causes an increased risk of any-grade decreased appetite, nausea, vomiting and diarrhea with no significant increase in the higher-grade toxicities compared with control arms. These results should be taken seriously in the ongoing trials combining CDK 4/6 inhibitors with cytotoxic chemotherapy. Furthermore, choice of proper anti-emetics and antidiarrheals should be revised according to the drug-interaction profile of each CDK4/6 inhibitor separately.
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